Human clinical study on grape seed extract presented at 13th World Congress on Heart Disease

The findings of the second human clinical trial conducted by UC Davis on the effects of grape seed extract on elevated blood pressure was presented at the scientific sessions of the 13th World Congress on Heart Disease. The conference, held July 28-31, 2007 in Vancouver, BC, Canada, was sponsored by the International Academy of Cardiology.

The study was conducted by researchers at UC Davis School of Medicine and Medical Center and focused on adults suffering from pre-hypertension, or elevated blood pressure, which increases the risk of having a heart attack or stroke. The findings indicated that a unique grape seed extract, supplied by Polyphenolics, does help to lower blood pressure in pre-hypertensive patients

In the study, pre-hypertensive subjects – defined as having systolic blood pressure between 120 and 139 mmHG and/or a diastolic pressure between 80 and 89 mmHG – were randomly placed into a placebo group or an experimental group. The experimental group received 300 mg. of the unique grape seed extract called MegaNatural-BP, developed and made by Polyphenolics, daily for eight weeks.

Those patients who were given the grape seed extract showed an 8 mm drop in systolic pressure versus zero for those in the placebo group, and a 5 mm drop in diastolic pressure versus an increase of 2 mm in the placebo group.

The research was funded by Polyphenolics, a division of Constellation Wines U.S. and a leading manufacturer of ingredients for the nutritional and beverage industries. Its extracts are produced in Constellation Wines U.S. wineries in California from unfermented grapes, using a patented, solvent-free, water extraction process. For more information, call 480-883-6716 or visit www.polyphenolics.com.